Merit Medical Systems, Inc. (MMSI) is engaged in the design, development, manufacturing, and worldwide commercialization of disposable medical products. These devices are ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $1.04 · Revenue $410.38M · 8 analysts
Est. EPS $1.13 · Revenue $425.03M · 7 analysts
Est. EPS $4.30 · Revenue $1.64B · 7 analysts
Est. EPS $1.02 · Revenue $408.42M · 2 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $1.5B | +11.7% | +9.7% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $128.5M | +6.8% | -5.3% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +48.7% | +2.6% | +6.2% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +12.2% | +6.1% | +25.5% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +8.5% | -4.4% | -13.7% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $212.5M | +16.3% | +113.6% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +14.0% | +4.1% | +94.8% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 56.7% | -1.6% | -3.3% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 4.34x | +1.6% | -17.4% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $2.7B | +11.1% | +5.3% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 2.13 vs 3.75 | -43.2% | 0.65 vs 1.04 | -37.2% |
| Revenue Surprise | $1.5B vs $1.5B | +0.2% | $418.8M vs $410.4M | +2.1% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Lewis Sheri | — | — | — | 0 | — |
| Aug 24, 2026 | Peterson Neil W. | officer: CHIEF OPERATING OFFICER | Common Stock, No Par Value | D | 7,500 | $90.45 |
| Aug 24, 2026 | Voigt Michel J. | officer: CHIEF HUMAN RESOURCES OFFICER | Common Stock, No Par Value | D | 650 | — |
| Aug 4, 2026 | Peterson Neil W. | officer: CHIEF OPERATING OFFICER | Common Stock, No Par Value | D | 21,449 | $85.00 |
| Jun 15, 2026 | Voigt Michel J. | officer: CHIEF HUMAN RESOURCES OFFICER | Common Stock, No Par Value | D | 65 | — |
Operator: Welcome to Merit Medical Systems' Second Quarter 2026 Earnings Conference Call. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. I would now like to turn the call over to Martha Aronson, Merit Medical Systems' President and Chief Executive Officer. Martha Aronson: Thank you, operator, and welcome, everyone. I am joined on the call today by Raul Parra, our Chief Financial Officer and Treasurer; and Brian Lloyd, our Chief Legal Officer and Corporate Secretary. Brian, would you mind taking us through the safe harbor statements, please? Brian Lloyd: Thanks, Martha. This presentation contains forward-looking statements that receive safe harbor protection under federal securities laws. Although we believe these forward-looking statements are based upon reasonable assumptions, they are subject to risks and uncertainties. The realization of any of these risks or uncertainties as well as extraordinary events or transactions impacting our company could cause actual results to differ materially from the expectations and projections expressed or implied by our forward-looking statements. In addition, any forward-looking statements represent our views only as of today, July 30, 2026, and should not be relied upon as representing our views as of any other date. We specifically disclaim any obligation to update such statements, except as required by applicable law. Please refer to the sections entitled Cautionary Statement regarding forward-looking statements in today's press release and presentation for important information regarding such statements. For a discussion of factors that could cause actual results to differ from these forward-looking statements, please also refer to our most recent filings with the SEC, which are available on our website. Our financial statements are prepared in accordance with accounting principles, which are generally accepted in the United States. However, we believe certain non-GAAP financial measures provide investors with useful information regarding the underlying business trends and performance of our ongoing operations and can be useful for period-over-period comparisons of such operations. This presentation also contains certain non-GAAP financial measures. A reconciliation of non-GAAP financial measures to the most directly comparable U.S. GAAP measures is included in today's press release and presentation furnished to the SEC under Form 8-K. Please refer to the sections of our press release and presentation entitled Non-GAAP Financial Measures for important information regarding non-GAAP financial measures discussed on this call. Readers should consider non-GAAP financial measures in addition to, not as a substitute for financial reporting measures prepared in accordance with GAAP. Please note that these calculations may not be comparable with similarly titled measures of other companies. Both today's press release …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Neil Peterson | Chief Operating Officer | USD 1,258,498 | Male | 1966 | Active |
Raul Parra Jr. | Chief Financial Officer & Treasurer | USD 1,237,275 | Male | 1979 | Active |
Brian G. Lloyd | Chief Legal Officer & Corporate Secretary | USD 1,216,342 | Male | 1961 | Active |
Michel J. Voigt | Chief Human Resources Officer | USD 816,792 | Male | 1973 | Active |
Martha Goldberg Aronson | President, Chief Executive Officer & Director | USD 501,385 | Female | 1967 | Active |
Clay Creamer | Executive Vice President of Manufacturing Finance & Strategy | — | Male | — | Active |
Jim Mottola | Executive Vice President of Global Research & Development | — | Male | — | Active |
Mark Butler | Executive Vice President of Merit Medical EMEA | — | Male | — | Active |
Alisha Jerauld | Sustainability Council Chair and Vice President of Environment, Social & Governance | — | Female | — | Active |
Jason Treft | Chief Information Officer | — | Male | — | Active |
John Knorpp | Chief Regulatory Affairs Officer | — | Male | — | Active |
Sarah Comstock | Vice President of Global Communications | — | Female | — | Active |
Ricardo Alvarez | Managing Director of Operation Merit Medical Tijuana | — | Male | — | Active |
MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.
Freestone Grove Partners LP purchased a new position in Merit Medical Systems, Inc. (NASDAQ: MMSI) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,554 shares of the medical instruments supplier's stock, valued at approximately $1,148,000. Other hedge funds and other
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
American Capital Management Inc. acquired a new stake in Merit Medical Systems, Inc. (NASDAQ: MMSI) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 104,967 shares of the medical instruments supplier's stock, valued at approximately $7,278,000. American Capital Management
Merit Medical's growth case is strengthening as launches, acquisitions and therapeutic products broaden its mix, but its premium valuation raises the execution bar.
